AvantGuard's journey at TechCrunch Disrupt 2023 was nothing short of amazing! Ted Eveleth, AvantGuard's CEO, showcased the groundbreaking antimicrobial technology, which turns chlorine into the ultimate surface protectant.
Covered in TechCrunch's article is exactly what AvantGuard is doing differently than your average chlorine-based disinfectant. Beyond surfaces, this innovative polymer has a wide range of potential uses, spanning water treatment, acne treatment, topical anti-fungal solutions, wound dressings, and long-term protection for medical devices, with an estimated market impact exceeding $70 billion.
With over $8 million in grants and $4 million in equity funding, AvantGuard is blazing a trail in antimicrobial technology. We're forging strategic partnerships, developing new solutions, and formalizing patents.
If you're curious about our revolutionary technology and what sets us apart, you can get the full scoop in TechCrunch’s article!
You can also read the article on Yahoo.
AvantGuard™ is blurring the lines between antibiotics, antiseptics, and disinfectants, creating innovative solutions that manage surfaces, including skin, and provide long-term protection against viruses, bacteria, and fungi/mold. The company’s proprietary combinations of specialty molecules and polymers are customized to provide prolonged antimicrobial efficacy to a wide range of surfaces and materials, a $1B opportunity that is critical to ensuring a healthier and safer world.